These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 26041041)

  • 1. Serological Correlates of Protection against a GII.4 Norovirus.
    Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
    Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
    Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
    Atmar RL; Baehner F; Cramer JP; Lloyd E; Sherwood J; Borkowski A; Mendelman PM;
    J Infect Dis; 2019 Jul; 220(4):603-614. PubMed ID: 31001633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
    Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.
    Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D;
    Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
    Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
    J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children.
    Malm M; Uusi-Kerttula H; Vesikari T; Blazevic V
    J Infect Dis; 2014 Dec; 210(11):1755-62. PubMed ID: 24970849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.
    Atmar RL; Ettayebi K; Ramani S; Neill FH; Lindesmith L; Baric RS; Brinkman A; Braun R; Sherwood J; Estes MK
    J Infect Dis; 2024 May; 229(5):1402-1407. PubMed ID: 37781879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.
    Kim L; Liebowitz D; Lin K; Kasparek K; Pasetti MF; Garg SJ; Gottlieb K; Trager G; Tucker SN
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
    Atmar RL; Baehner F; Cramer JP; Song E; Borkowski A; Mendelman PM;
    J Infect Dis; 2016 Sep; 214(6):845-53. PubMed ID: 27354368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
    Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.
    Leroux-Roels G; Cramer JP; Mendelman PM; Sherwood J; Clemens R; Aerssens A; De Coster I; Borkowski A; Baehner F; Van Damme P
    J Infect Dis; 2018 Jan; 217(4):597-607. PubMed ID: 29140444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norovirus vaccine against experimental human Norwalk Virus illness.
    Atmar RL; Bernstein DI; Harro CD; Al-Ibrahim MS; Chen WH; Ferreira J; Estes MK; Graham DY; Opekun AR; Richardson C; Mendelman PM
    N Engl J Med; 2011 Dec; 365(23):2178-87. PubMed ID: 22150036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.